Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.30 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794786 | 1.00 | CTSB (0.37) | CTSBCTSSHDAC4HDAC1CYP3A4 | |
| SCHEMBL1646314 | 1.00 | CTSB (0.37) | CTSBCTSSHDAC4HDAC1CYP3A4 | |
| SCHEMBL11976285 | 0.91 | CTSB (0.41) | CTSBCTSSHDAC4HDAC1CYP3A4 | |
| SCHEMBL13082879 | 0.91 | CTSB (0.41) | CTSBCTSSHDAC4HDAC1CYP3A4 | |
| SCHEMBL11976288 | 0.89 | CTSB (0.39) | CTSBCTSSCYP3A4 | |
| SCHEMBL1646220 | 0.89 | CTSB (0.39) | CTSBCTSSCYP3A4 | |
| SCHEMBL1683141 | 0.89 | CTSB (0.39) | CTSBCTSSCYP3A4 | |
| SCHEMBL3793073 | 0.89 | CTSB (0.39) | CTSBCTSSCYP3A4 | |
| SCHEMBL13711265 | 0.89 | CTSB (0.39) | CTSBCTSSHDAC4HDAC1CYP3A4 | |
| SCHEMBL11976286 | 0.89 | CTSB (0.39) | CTSBCTSSHDAC4HDAC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | CTSB 550/4885CTSS 916/4885HDAC4 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.